Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients

Management of PD-1 blockade resistance in metastatic melanoma (MM) remains challenging. Immunotherapy or chemotherapy alone provides limited benefit in this setting. Chemo-immunotherapy (CIT) has demonstrated favorable efficacy and safety profiles in lung cancer. Our pre-clinical study showed that i...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Melanoma Res
Hoofdauteurs: Vera Aguilera, Jesus, Paludo, Jonas, McWilliams, Robert R., Zhang, Henan, Li, Ying, Kumar, Anagha B., Failing, Jarrett, Kottschade, Lisa A., Block, Matthew S., Markovic, Svetomir N., Dong, Haidong, Dronca, Roxana S., Yan, Yiyi
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Lippincott Williams & Wilkins 2020
Onderwerpen:
Original Articles: Clinical research
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7331824/
https://ncbi.nlm.nih.gov/pubmed/32404734
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CMR.0000000000000669
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items